Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen has announced positive data from the first three years of the open-label extension study of the Phase 3 fracture trial showing the efficacy of Prolia (denosumab) treatment in postmenopausal women with osteoporosis.
Subscribe to our email newsletter
Prolia is a therapy for the treatment of postmenopausal women with osteoporosis that specifically targets RANK Ligand, an essential regulator of osteoclasts.
The treatment over three years led to increase in bone mineral density (BMD) and consistent reduction in markers of bone turnover.
Results of the open-label extension study demonstrated that postmenopausal women with osteoporosis who received up to six years of continued Prolia treatment experienced cumulative gains of 15.2% at the lumbar spine and 7.55 at the total hip compared with baseline.